Early changes in the pharmacokinetic profile of vedolizumab-treated patients with IBD may predict response after dose optimisation.

    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.

Related Topics

    loading  Loading Related Articles